• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Perceptive Advisors Closes $515M Early-Stage Biotech Fund

by Jasmine Pennic 05/13/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Perceptive Advisors and biotech accelerator Xontogeny, focused on seed investment, incubation and collaboration, have raised their second venture capital fund, the Perceptive Xontogeny Ventures Fund II (PXV Fund II), totaling an over-subscribed $515 million. This more than triples Assets Under Management to more than $700M in less than two years.

– The PXV Fund aspires to be “entrepreneur-friendly” with “right-sized” Series A investing in the range of $20-40 million with capacity to participate in subsequent Series B financings helping early-stage life science founders advance their assets and establish proof-of-concept data and the next significant value inflection in approximately 18 to 24 months.

– The PXV Funds are focused exclusively on life sciences technologies across a broad range of therapeutic areas with a greater emphasis on drug technologies and a lesser focus on early drug and discovery platforms. The primary goal of PXV Funds’ Series A and subsequent Series B financings will be advancing products and technologies from preclinical stages through early clinical development and the generation of proof-of-concept data in patients.

– This news builds on the PXV Fund I, which made 10 investments including leading 8 Series As and participation in 3 syndicates for Series Bs, including the recent $120M Forge Biologics Series B.

Leadership

The PXV Funds are led by Chris Garabedian, Portfolio Manager, who also serves as Chairman and CEO of Xontogeny. Xontogeny is a Boston-based accelerator that provides seed investments along with strategic and operational support to early-stage life sciences companies through its professional staff and network of consultants and service providers.

The PXV Fund II Investment Committee consists of Joe Edelman, CEO of Perceptive Advisors, Adam Stone, Chief Investment Officer of Perceptive Advisors and Chris Garabedian, Portfolio Manager. Fred Callori, Xontogeny’s SVP of Corporate Development and Ben Askew, PhD, Xontogeny’s Head of R&D, are also Partners in PXV Fund II.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biotech

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |